Skip to main content
    D

    Dyadic International Inc (DYAI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.32
    -0.01 (-2.14%)

    Market Cap: $13.10M

    Last updated: Nov 17, 2026 at 10:46 AM ET

    Dyadic International Inc (DYAI) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Dyadic International (DYAI) is expected to report earnings on Mar 23, 2027. In the quarter ended Sep 30, 2026, Dyadic International reported EPS of -$0.05, below the -$0.03 estimate. It beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    29%(9/31)
    Avg Surprise
    -42.05%

    Upcoming Estimates

    Reports Mar 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.01
    Range-$0.02 - $0.04
    5 analysts
    Revenue Consensus
    $3.05M
    Range$1.47M - $4.71M
    5 analysts

    Next Report

    DYAI has an expected report date of Mar 23, 2027.

    DYAI Earnings Call

    The latest DYAI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 31 quarters below that had an estimate, DYAI beat 9, missed 17 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $449101, down 61.3% from $1.16M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.05-$0.03-$0.06 - -$0.03-66.67%MissN/A30 up, 0 downNov 12, 2026$449101
    Jun 30, 2026-$0.06-$0.03-$0.04 - -$0.03-100.00%MissN/A30 up, 0 downAug 12, 2026$961138
    Mar 31, 2026-$0.05-$0.04-$0.05 - -$0.04-25.00%MissN/A21 up, 0 downMay 13, 2026$1.11M
    Dec 31, 2025-$0.04-$0.04N/A-11.03%MissN/A11 up, 0 downMar 25, 2026$235716
    Sep 30, 2025-$0.06-$0.04-$0.06 - -$0.03-50.00%MissN/A30 up, 0 downNov 12, 2025$1.16M
    Jun 30, 2025-$0.06-$0.06N/A0.00%In lineN/AN/A0 up, 0 downAug 13, 2025$463449
    Mar 31, 2025-$0.07N/AN/AN/AN/AN/AN/A0 up, 0 downMay 14, 2025$183100
    Dec 31, 2024-$0.05-$0.04N/A-25.00%MissN/A10 up, 0 downMar 26, 2025$817376
    Sep 30, 2024-$0.01-$0.07-$0.07 - -$0.07+85.71%BeatN/A10 up, 0 downNov 12, 2024$1.96M
    Jun 30, 2024-$0.07-$0.06-$0.07 - -$0.06-16.67%MissN/A20 up, 0 downAug 13, 2024$385896
    Mar 31, 2024-$0.07-$0.07N/A+0.43%Beat-332.3%N/A0 up, 0 downMay 14, 2024$334617
    Dec 31, 2023-$0.08-$0.06-$0.08 - -$0.05-33.33%MissN/A20 up, 0 downMar 28, 2024$686535
    Sep 30, 2023-$0.06-$0.06N/A0.00%In lineN/A10 up, 0 downNov 8, 2023$397060
    Jun 30, 2023-$0.07-$0.05-$0.08 - -$0.02-40.00%MissN/A20 up, 0 downAug 9, 2023$837159
    Mar 31, 2023$0.03-$0.03N/A+200.00%BeatN/AN/A0 up, 0 downMay 10, 2023$978052
    Dec 31, 2022-$0.07-$0.07-$0.10 - -$0.070.00%In lineN/A20 up, 0 downMar 29, 2023$743726
    Sep 30, 2022-$0.06-$0.09-$0.11 - -$0.08+33.33%BeatN/A20 up, 0 downNov 10, 2022$879597
    Jun 30, 2022-$0.12-$0.07-$0.12 - -$0.05-71.43%MissN/A30 up, 1 downAug 10, 2022$658553
    Mar 31, 2022-$0.09-$0.14N/A+35.71%BeatN/A20 up, 0 downMay 12, 2022$648427
    Dec 31, 2021-$0.15-$0.02-$0.06 - $0.01-650.00%MissN/A20 up, 0 downMar 29, 2022$313290
    Sep 30, 2021-$0.06-$0.10-$0.10 - -$0.09+40.00%BeatN/A2N/ANov 10, 2021$692929
    Jun 30, 2021-$0.14-$0.09-$0.09 - -$0.09-55.56%MissN/A2N/AAug 12, 2021$937092
    Mar 31, 2021-$0.12$0.09$0.09 - $0.09-233.33%MissN/A1N/AMay 13, 2021$460520
    Dec 31, 2020-$0.07-$0.08-$0.08 - -$0.08+12.50%BeatN/A2N/AMar 30, 2021$345917
    Sep 30, 2020-$0.09-$0.07-$0.09 - -$0.07-28.57%MissN/A2N/ANov 12, 2020$416361
    Jun 30, 2020-$0.10-$0.07-$0.07 - -$0.02-42.86%MissN/A2N/AAug 13, 2020$524271
    Mar 31, 2020-$0.08-$0.02-$0.02 - -$0.02-300.00%MissN/A1N/AMay 14, 2020$315372
    Dec 31, 2019-$0.07-$0.07N/A0.00%In lineN/AN/AN/AMar 30, 2020$433168
    Sep 30, 2019-$0.06-$0.07N/A+14.29%BeatN/AN/AN/ANov 13, 2019$454507
    Jun 30, 2019-$0.10-$0.07N/A-42.86%MissN/AN/AN/AAug 13, 2019$390874
    Mar 31, 2019-$0.08N/AN/AN/AN/AN/AN/AN/AMay 9, 2019$402527
    Dec 31, 2018-$0.02-$0.06N/A+66.67%BeatN/AN/AN/AMar 27, 2019$686875
    Sep 30, 2018-$0.06-$0.06N/A0.00%In lineN/AN/AN/ADec 18, 2018$262960
    Jun 30, 2018-$0.06N/AN/AN/AN/AN/AN/AN/AAug 9, 2018$161286
    Mar 31, 2018-$0.07N/AN/AN/AN/A-200.0%N/AN/AMay 10, 2018$184330
    Dec 31, 2017-$0.02N/AN/AN/AN/AN/AN/AN/AMar 27, 2018$157000
    Sep 30, 2017-$0.05N/AN/AN/AN/AN/AN/AN/ANov 9, 2017$272491
    Jun 30, 2017-$0.05N/AN/AN/AN/A-440.1%N/AN/AAug 10, 2017$207402
    Mar 31, 2017$0.07N/AN/AN/AN/AN/AN/AN/AMay 11, 2017$121527
    Dec 31, 2016-$0.06N/AN/AN/AN/A-103.7%N/AN/AMar 15, 2017$491050
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.23, after -$0.20 the year before. It was -$0.10 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.23N/A
    Dec 31, 2024-$0.20N/A
    Dec 31, 2023-$0.18N/A
    Dec 31, 2022-$0.34N/A
    Dec 31, 2021-$0.47N/A
    Dec 31, 2020-$0.34N/A
    Dec 31, 2019-$0.31N/A
    Dec 31, 2018-$0.21N/A
    Dec 31, 2017-$0.05N/A
    Dec 31, 2016-$0.10N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,9777
    2026Q2Jun 30, 20264,4496
    2026Q1Mar 31, 20264,7379
    2025Q4Dec 31, 20256,1918
    2025Q3Sep 30, 20256,0568
    2025Q2Jun 30, 20254,77610
    2025Q1Mar 31, 20254,3047
    2024Q3Sep 30, 20245,4836

    2026Q3 Earnings Call

    Opening remarks

    Ping Rawson CFO Thank you. Good evening, and welcome, everyone, to Dyadic's Third Quarter 2026 Conference Call. I hope you have had the opportunity to review Dyadic's press release announcing financial results for the quarter ended September 30, 2026. You may access our release under the Investors section of the company's website at dyadic.com. Before we begin, I want to let you know that due to a Microsoft Outlook issue that has impacted many organizations, including Dyadic, we have not yet filed our quarterly report on Form 10-Q for the quarter ended September 30, 2026. We expect to file the Form 10-Q as soon as the system is back online and within the SEC filing deadline. The financial results we will discuss today are those in our press release, and they will be reflected in the Form 10-Q. On today's call, our President and Chief Operating Officer, Joe Hazelton, will review our Q3 2026 business and corporate highlights and provide commentary on the strategic direction of the company. Our CEO, Mark Emalfarb, will provide an update on our biopharmaceutical programs, and I will follow with a review of our financial results in more detail, after which we will hold a brief question-and-answer session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements, which involve risks and uncertainties and other factors that could cause Dyadic's actual results, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. Dyadic expressly disclaims any duty to provide updates to its forward-looking statements, whether because of new information, future events or otherwise. Participants are directed to the risk factors set forth in Dyadic's reports filed with the SEC. It is now my pleasure to pass the call to our President and COO, Joe Hazelton. Joe?

    Joseph Hazelton President and COO Thanks, Ping, and thank you, everyone, for joining us today. Over the past several quarters, we've discussed Dyadic's transition from primarily developing protein production technologies toward building commercial businesses around our C1 and Dapibus platforms. During the third quarter, we continued making progress in that transition through initial direct product sales, broader distribution, additional partner-commercialized products, and advancing discussions with companies interested in our technologies and protein production portfolio. While these developments are encouraging, I want to put them in perspective. Our direct commercial sales remain modest, and customer qualification and adoption are taking longer than we originally anticipated. While we still have work ahead of us to establish meaningful and recurring product revenue, we are beginning to demonstrate that our protein production platforms can support commercial products through multiple business models, including direct sales, distribution, licensing, and partner-led commercialization.

    Frequently Asked Questions About DYAI

    When is Dyadic International's next earnings date?

    Dyadic International's next earnings report is expected for Mar 23, 2027.

    Did DYAI beat earnings estimates last quarter?

    No. Dyadic International reported EPS of -$0.05 for the quarter ended Sep 30, 2026, below the -$0.03 estimate by 66.67%.

    What EPS do analysts expect from DYAI next quarter?

    The consensus EPS estimate for Dyadic International for the quarter ending Dec 31, 2026 is $0.01 from 5 analysts, with estimates from -$0.02 to $0.04.

    How often does DYAI beat earnings estimates?

    Dyadic International beat the EPS estimate in 1 of the 8 most recent quarters that had an estimate, with an average surprise of -24.00%.